Virginia's Advanced Pharmaceutical Manufacturing Tech Hub Secures $15.97 Million Federal Investment for End-to-End Domestic Medicine Commercialization
核心洞察
The U.S. Economic Development Administration has awarded $15.97 million to launch the End-to-End Commercialization Project led by Civica, Inc., with support from Phlow Corp. and Occam Systems (搜索).
The project will establish an integrated domestic pathway from key starting materials through API manufacturing, finished dose formulation, FDA approval, and commercial delivery to patients.
Four essential sterile injectable medicines—ketamine, midazolam, norepinephrine, and succinylcholine—will be the initial focus, targeting emergency, anesthesia, and critical care settings.
The Alliance for Building Better Medicine, the coalition leading Virginia's Advanced Pharmaceutical Manufacturing (APM) Tech Hub, has announced a $15.97 million investment from the U.S. Economic Development Administration (EDA) to launch the End-to-End (E2E) Commercialization Project. The initiative, led by Civica, Inc. (Civica Rx) and supported by Phlow Corp. and Occam Systems (搜索), aims to establish a fully domestic commercialization pathway connecting pharmaceutical innovation, manufacturing, and patient delivery—from inputs to finished medicines.
The project represents the latest milestone for the Alliance, which includes 55 partners spanning industry, academia, workforce development, government, nonprofit organizations, and economic development, all working to strengthen America's pharmaceutical manufacturing ecosystem and expand domestic manufacturing capacity.
An Integrated Domestic Supply Chain
The End-to-End Commercialization Project creates a coordinated national ecosystem in which each partner contributes a distinct capability. Occam Systems (搜索) will accelerate the development of domestically sourced key starting materials (KSMs), Phlow Corp. will advance domestic active pharmaceutical ingredient (API) manufacturing, and Civica, Inc. will lead finished dose formulation, regulatory approval, commercial manufacturing, and delivery of medicines to patients.
The project will initially focus on four essential sterile injectable medicines used every day in emergency, anesthesia, and critical care settings: ketamine, midazolam, norepinephrine, and succinylcholine. These drugs represent critical therapies where supply disruptions can have immediate and severe consequences for patient care.
"This milestone reflects what becomes possible when organizations commit to solving challenges that no single company can solve alone," said Robby Demeria, Chief of Staff of Phlow Corp. and Founding Board Chair of the Alliance for Building Better Medicine. "From the beginning, the Alliance has been built on the belief that lasting progress comes through collaboration."
Addressing National Supply Chain Vulnerabilities
Today, more than 130 million Americans rely on medicines produced through increasingly complex global manufacturing networks. Persistent shortages continue to affect many critical therapies, while decades of offshoring have shifted manufacturing capacity, technical expertise, and pharmaceutical innovation overseas. The End-to-End Commercialization Project is designed to strengthen America's ability to develop, commercialize, and manufacture medicines domestically while expanding U.S. capacity for both established and innovative therapies.
"Virginia is an emerging leader in advanced pharmaceutical manufacturing, and we are committed to uniting industry, researchers, educators, workforce partners, and public leaders around a shared goal: ensuring medicines are reliably developed and manufactured in the United States," said Governor Abigail Spanberger.
Building on Substantial Prior Investment
The project builds on more than $1.7 billion in prior federal, state, philanthropic, and private investment that helped establish Virginia's Advanced Pharmaceutical Manufacturing Tech Hub, as well as nearly $14 billion in public and private commitments announced across the broader ecosystem since 2020. In 2025 alone, Virginia announced more than $13 billion in advanced pharmaceutical manufacturing investments, including major commitments from AstraZeneca, Eli Lilly, and Merck.
Since the launch of the Tech Hub in 2023, the Commonwealth Center for Advanced Manufacturing (CCAM) has served as the fiscal and administrative lead on behalf of the Alliance for Building Better Medicine, providing the operational backbone that has supported coalition coordination, implementation, and execution.
"We are honored to lead this effort alongside an extraordinary coalition of partners committed to improving the resilience of America's medicine supply," said Ned McCoy, CEO of Civica. "This initiative aligns with our mission to ensure that essential medicines remain available, affordable, and reliably supplied for the hospitals, healthcare providers, and patients who depend on them every day."
A Collaborative Model for the Future
The Alliance's collective efforts have helped secure a Build Back Better Regional Challenge award, designation as the nation's Advanced Pharmaceutical Manufacturing Tech Hub, National Science Foundation Engines support, Good Jobs Challenge workforce funding, advanced manufacturing infrastructure investments, and more than 20 shared project wins spanning workforce development, manufacturing, innovation, and commercialization.
"This milestone reflects years of partnership, persistence, and shared commitment at the federal, state, regional, and local levels," said Joy Polefrone, Ph.D., Regional Innovation Officer for Virginia's APM Tech Hub and the Alliance for Building Better Medicine. "We are deeply grateful to Senators Mark Warner and Tim Kaine, Representative Jennifer McClellan, Governor Abigail Spanberger, Mayor Danny Avula, Mayor Sam Parham, and the many leaders who have championed this work from the beginning."